sulfonylurea

(redirected from Sulphonylurea)
Also found in: Dictionary, Medical, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to sulfonylurea

antidiabetic consisting of any of several drugs that reduce the level of glucose in the blood

References in periodicals archive ?
During Ramadan, one should reduce the dose of Sulphonylureas. He concluded his presentation by stating that now IDF-DAR has developed effective guidelines for management of diabetes during Ramadan.
In a phase 3 study, 469 patients of T2DM inadequately controlled with metformin and sulphonylurea, received canaglifozin 100 or 300 mg or placebo in once daily dosing.
Neonatal diabetes due to a dominant activating mutation of a [K.sub.ATP] channel gene (KCNJ11 or ABCC8) is usually sulphonylurea responsive (27, 28).
Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
This causes ER stress in the beta cell resulting in cell death and absolute insulin deficiency [52] which requires permanent insulin treatment [94], in stark contrast to the sulphonylurea sensitivity of patients with KCNJ11 mutations [53].
Poorly controlled elderly type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin.
Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
This helps in the early recognition of possible side effects such as hypoglycemia from some antiglycemic medications like sulphonylurea and insulin and the spatial trend of glucose profiles that may need dose adjustments.
Dapagliflozin also exerts a sustained benefit on systolic blood pressure, and causes a very consistent 2- to 3-kg decrease in body weight, no matter whether it's given alone or with metformin, insulin, or a sulphonylurea.
Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
Insulin prescription to 39 (19.5%) patients was second highest as monodrug; followed by Sulphonylurea to 34 (17.0%) patients.
Published in a leading diabetes journal produced by scientists from Cardi$ University, the study set out to compare the survival of diabetes patients prescribed with metformin with patients prescribed with another common diabetes drug called sulphonylurea.
Published in a leading diabetes journal, Diabetes, Obesity and Metabolism by scientists from Cardiff University, the study set out to compare the survival of diabetes patients prescribed with metformin with patients prescribed with another common diabetes drug called sulphonylurea. Importantly, the life expectancy of these cohorts was also compared against non-diabetics who were matched based on criteria that included age, gender, same general practice, smoking status and clinical status.
In recent years much attention is given to the use of sulphonylurea because of their high complexing nature with essential metals.
Interestingly, thiazolidinedione, an insulin sensitiser protected women against cancer (32 percent lowered risk) than an insulin secretagogue known as sulphonylurea. "What this study shows us is that using insulin secretagogues to increase insulin production correlates with an increased cancer risk in women with type 2 diabetes," Sangeeta Kashyap, who was involved with the study, said in a news release.